Albert Einstein College of Medicine

Adimab, LLC

Mapp Biopharmaceutical, Inc.

US Government As Represented by the Secretary of the Army

Harvard College

The Brigham and Women's Hospital, Inc.

University of Toronto

Whitehead Institute for Biomedical Research

Microbiotix, Inc.

Biopharmaceutical, Inc.

Kartik Chandran

Anna Z Wec

Laura M Walker

Larry Zeitlin

Zachary A Bornholdt

Jonathan R Lai

John M Dye

Sachdev Singh Sidhu

Julia Frei

James Cunningham

Gang Chen

Samantha Zak

Kyungae Lee

Tao Ren

Jayne F Koellhoffer

Elisabeth K Nyakatura

Terry L Bowlin

Thijn Reinout Brummelkamp

John D Williams

Arnab Basu

Donald T Moir

Jan E Carette

Debra M Mills

Sean Whelan

Lucas Tilmann Jae

Zachary D Aron

Matthijs Raaben

Jay P Barbor

Jayne F Koelhoffer

Kelly N Lively

Thijin R Brummelkamp

Peter J Nash

Rohit K Jangra

Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Monoclonal antibodies and cocktails for treatment of Ebola infections

The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GP) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

Broad spectrum inhibitors of filoviruses

Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick C1 (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

Methods of treating filovirus infections utilizing bispecific antibodies and fusion proteins that bind EBOV and NPC1

The present invention addresses a need for antibodies useful for filovirus infections.

Filovirus antibody

Described herein are compositions and methods for the prevention and treatment of ebolavirus infection certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Monoclonal antibodies and cocktails for treatment of ebola infections

The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.

Therapy for filovirus infection

Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

Bispecific antibodies and fusion proteins that bind to EBOV and NPC1

Methods and assays are disclosed for treating a subject with a hantavirus infection using an agent that binds to protocadherin-1 (PCDH1) or inhibits expression of protocadherin-1 (PCDH1).

Methods and assays for treating hantavirus infections

The present invention addresses a need for improved treatments for Filovirus infections.

The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.

Method of treating Ebola

Growing community of inventors

Brooklyn, NY, United States of America

Kartik Chandran